Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 100 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Follow-Up Questions
Who is the CEO of MoonLake Immunotherapeutics?
Dr. Jorge Santos Da Silva is the Chief Executive Officer of MoonLake Immunotherapeutics, joining the firm since 2022.
What is the price performance of MLTX stock?
The current price of MLTX is $10.43, it has decreased 0% in the last trading day.
What are the primary business themes or industries for MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics belongs to Biotechnology industry and the sector is Health Care
What is MoonLake Immunotherapeutics market cap?
MoonLake Immunotherapeutics's current market cap is $670.3M
Is MoonLake Immunotherapeutics a buy, sell, or hold?
According to wall street analysts, 17 analysts have made analyst ratings for MoonLake Immunotherapeutics, including 11 strong buy, 11 buy, 2 hold, 0 sell, and 11 strong sell
